360 related articles for article (PubMed ID: 29082645)
1. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
Wang ML; Chen EQ; Zhang DM; Du LY; Yan LB; Zhou TY; Lei XZ; Lei BJ; Lu JJ; Liao J; Tang H
J Viral Hepat; 2017 Nov; 24 Suppl 1():21-28. PubMed ID: 29082645
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
[TBL] [Abstract][Full Text] [Related]
4. [Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].
Xu J; Bao L; Wang Y; Yang L; Li WT; Zhao ZH; Li Y
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):288-293. PubMed ID: 29996341
[No Abstract] [Full Text] [Related]
5. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
7. LAM add-on ADV combination therapy or ETV monotherapy for CHB patients with suboptimal response to ADV.
Jia H; Ding F; Chen J; Zhang Y; Xiang D; Lian J; Zeng L; Yu L; Hu J; Li Y; Lu Y; Liu Y; Zheng L; Li L; Yang Y
Ann Hepatol; 2015; 14(2):175-80. PubMed ID: 25671826
[TBL] [Abstract][Full Text] [Related]
8. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
Wang JC; He LL; Chen Q
Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
[TBL] [Abstract][Full Text] [Related]
9. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.
Lee M; Oh S; Lee HJ; Yeum TS; Lee JH; Yu SJ; Kim HY; Yoon JH; Lee HS; Kim YJ
J Viral Hepat; 2014 Dec; 21(12):873-81. PubMed ID: 24351112
[TBL] [Abstract][Full Text] [Related]
10. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
11. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
12. [Long-term efficacy and safety of telbivudine as monotherapy and as combination therapy with adefovir dipivoxil in HBeAg-positive chronic hepatitis B patients].
Liu Y; Liu L; Peng D; Li W; Du Y; Jia T; Chang L; Li H
Zhonghua Gan Zang Bing Za Zhi; 2014 Mar; 22(3):181-4. PubMed ID: 24824118
[TBL] [Abstract][Full Text] [Related]
13. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
14. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
Woo HY; Park JY; Bae SH; Kim CW; Jang JY; Tak WY; Kim DJ; Kim IH; Heo J; Ahn SH
Clin Mol Hepatol; 2020 Jul; 26(3):352-363. PubMed ID: 32460460
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
[TBL] [Abstract][Full Text] [Related]
16. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
[TBL] [Abstract][Full Text] [Related]
17. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
[TBL] [Abstract][Full Text] [Related]
18. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the 48-week efficacy of Lamivudine plus Adefovir or Entecavir monotherapy in patients with HBeAg negative hepatitis following Lamivudine treatment failure.
Zhang Q; Zhang L; Xing Y; Qin Y; Liu G
Acta Gastroenterol Belg; 2019; 82(1):31-34. PubMed ID: 30888751
[TBL] [Abstract][Full Text] [Related]
20. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
Shi H; Han Z; Liu J; Xue J; Zhang S; Zhu Z; Xia J; Huang M
Med Sci Monit; 2017 Nov; 23():5230-5236. PubMed ID: 29095799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]